Clearside Biomedical Inc
CLM
Company Profile
Business description
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing a proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.
Contact
900 North Point Parkway
Suite 200
AlpharettaGA30005
USAT: +1 678 270-3631
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
32
Stocks News & Analysis
stocks
James Hardie transfers of share listing to New York Stock Exchange
The change is a result of the controversial Azek acquisition.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,926.20 | 80.60 | -0.89% |
| CAC 40 | 7,805.89 | 16.78 | -0.21% |
| DAX 40 | 24,289.32 | 0.19 | -0.00% |
| Dow JONES (US) | 44,342.19 | 142.30 | -0.32% |
| FTSE 100 | 8,995.17 | 3.05 | 0.03% |
| HKSE | 24,994.14 | 168.48 | 0.68% |
| NASDAQ | 20,895.65 | 10.01 | 0.05% |
| Nikkei 225 | 39,819.11 | 82.08 | -0.21% |
| NZX 50 Index | 12,961.51 | 81.11 | 0.63% |
| S&P 500 | 6,296.79 | 0.57 | -0.01% |
| S&P/ASX 200 | 8,668.20 | 89.00 | -1.02% |
| SSE Composite Index | 3,559.79 | 25.31 | 0.72% |